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Abstract
Prior efforts to image cholinergic projections in human brain in vivo had significant technical lim-
itations. We used the vesicular acetylcholine transporter (VAChT) ligand [18F]fluoroethoxyben-
zovesamicol ([18F]FEOBV) and positron emission tomography to determine the regional
distribution of VAChT binding sites in normal human brain. We studied 29 subjects (mean age
47 [range 20–81] years; 18 men; 11 women). [18F]FEOBV binding was highest in striatum, inter-
mediate in the amygdala, hippocampal formation, thalamus, rostral brainstem, some cerebellar
regions, and lower in other regions. Neocortical [18F]FEOBV binding was inhomogeneous with
relatively high binding in insula, BA24, BA25, BA27, BA28, BA34, BA35, pericentral cortex, and
lowest in BA17–19. Thalamic [18F]FEOBV binding was inhomogeneous with greatest binding in
the lateral geniculate nuclei and relatively high binding in medial and posterior thalamus. Cere-
bellar cortical [18F]FEOBV binding was high in vermis and flocculus, and lower in the lateral cor-
tices. Brainstem [18F]FEOBV binding was most prominent at the mesopontine junction, likely
associated with the pedunculopontine–laterodorsal tegmental complex. Significant [18F]FEOBV
binding was present throughout the brainstem. Some regions, including the striatum, primary
sensorimotor cortex, and anterior cingulate cortex exhibited age-related decreases in [18F]
FEOBV binding. These results are consistent with prior studies of cholinergic projections in
other species and prior postmortem human studies. There is a distinctive pattern of human neo-
cortical VChAT expression. The patterns of thalamic and cerebellar cortical cholinergic terminal
distribution are likely unique to humans. Normal aging is associated with regionally specific
reductions in [18F]FEOBV binding in some cortical regions and the striatum.
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1 | INTRODUCTION
Acetylcholine (ACh) is the primary neurotransmitter of several CNS
neuron populations. These include neurons of the basal forebrain
(BF) complex projecting to numerous cortical regions, striatal choliner-
gic interneurons, the medial habenula–interpeduncular nucleus pro-
jection, projections of the pedunculopontine–laterodorsal tegmental
(PPN–LDT) complex, the parabigeminal nucleus, some medial vestibu-
lar complex (MVC) neurons, and brainstem motor and autonomic
Abbreviations: AC, anterior cingulate cortex; ACh, acetylcholine; AChase, ace-
tylcholinesterase; AD, Alzheimer disease; AM, amygdala; BF, basal forebrain;
ChAT, choline acetyltransferase; FEOBV, fluoroethoxybenzovesamicol; FL, floc-
culus; HIP, hippocampal formation; LG, lateral geniculate nucleus; MP, meso-
pontine; MP4A, N-methyl-4-piperidyl acetate; MVC, medial vestibular complex;
PD, Parkinson disease; PET, positron emission tomography; PMP, methyl-
4-piperidinyl propionate; PPN-LDT, pedunculopontine-laterodorsal tegmental
complex; SMC, sensorimotor cortex; SPECT, single photon emission computed
tomography; SUVR, standardized uptake value ratio; THAL, thalamus; VAChT,
vesicular acetylcholine transporter; VER, vermis
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neurons. BF cholinergic pathways participate in the modulation of
important cognitive functions such as attention and executive func-
tion (Ballinger, Ananth, Talmage, & Role, 2016; Hasselmo & Sarter,
2011; Prado, Janickova, Al-Onaizi, & Prado, 2017). Projections of the
PPN–LDT complex may play important roles in the regulation of sleep
and waking, and some data implicates these neurons in control of bal-
ance and gait (Gut & Winn, 2016; Mena-Segovia & Bolam, 2017; Pie-
naar, Vernon, & Winn, 2016). Striatal cholinergic interneurons are the
subject of intense investigations and play important roles in the con-
trol of a variety of functions mediated by the striatal complex
(Deffains & Bergman, 2015; Gonzales & Smith, 2015; Tanimura
et al., 2017).
Abnormalities of some of these pathways are implicated in neuro-
logic and psychiatric disease, particularly Alzheimer disease (AD), Par-
kinson disease (PD), and tobacco abuse. Degeneration of the BF
complex is documented well in AD and PD, and degeneration of cho-
linergic PPN–LDT neurons may drive important aspects of declining
gait and balance functions in PD and Progressive Supranuclear Palsy
(Bohnen et al., 2012; Gilman et al., 2010; Hirsch, Graybiel, Duyck-
aerts, & Javoy-Agid, 1987; Mesulam, 2013; Mufson, Ginsberg, Ikono-
movic, & DeKosky, 2003; Schliebs & Arendt, 2011). Augmenting
cholinergic neurotransmission with acetylcholinesterase inhibitors is
an accepted treatment for dementias, including AD, Lewy body
dementia, and PD-associated dementia. Anti-muscarinic cholinergic
agents are used for the treatment of dystonias and for treatment of
PD-associated tremor. Manipulations of cholinergic neurotransmission
are being pursued to improve gait and balance functions in PD
(Chung, Lobb, Nutt, & Horak, 2010; Henderson et al., 2016; Kucinski,
De Jong, & Sarter, 2017; Li et al., 2015). Nicotinic cholinergic recep-
tors mediate the addictive effects of nicotine and drugs active at this
receptor family are used to treat nicotine addiction (Anthenelli et al.,
2016). Improved understanding of the organization of cholinergic
pathways in the human brain is relevant to efforts to expand useful
cholinergic pharmacology in the treatment of human neurologic and
psychiatric diseases.
Prior investigations in other species, including nonhuman pri-
mates, and work with postmortem human tissues provided consider-
able information about the organization of human brain cholinergic
pathways (Albin, Morgan, Higgins, & Frey, 1994; Barmack, Baugh-
man, & Eckenstein, 1992; Barmack, Baughman, Eckenstein, & Shojaku,
1992; de Lacalle et al., 1994; De Lacalle, Hersh, & Saper, 1993; Emre,
Heckers, Mash, Geula, & Mesulam, 1993; Fitzpatrick, Diamond, &
Raczkowski, 1989; Fukushima et al., 2001; Gilmor et al., 1996, 1999;
Heckers, Geula, & Mesulam, 1992; Ichikawa, Ajiki, Matsuura, & Mis-
awa, 1997; Jaarsma et al., 1997; Kus et al., 2003; Levey, Hallanger, &
Wainer, 1987; Mahady, Perez, Emerich, Wahlberg, & Mufson, 2017;
Manaye et al., 1999; Mesulam, 2004; Mesulam & Geula, 1988; Mesu-
lam, Geula, Bothwell, & Hersh, 1989; Mesulam, Hersh, Mash, & Geula,
1992; Mesulam, Mash, Hersh, Bothwell, & Geula, 1992; Roghani, Shir-
zadi, Butcher, & Edwards, 1998; Schäfer, Eiden, & Weihe, 1998; Scha-
fer, Weihe, Erickson, & Eiden, 1995; Woolf, 1991; Woolf & Butcher,
1985, 1986, 1989; Woolf, Eckenstein, & Butcher, 1984; Zhang,
Zhou, & Yuan, 2016). Working with postmortem tissues has intrinsic
limitations and inferences from studies of other species may be con-
founded by inter-species differences.
To advance our understanding of the organization of cholinergic
pathways in humans, we assessed the regional distribution of human
brain cholinergic neuron terminals with [18F]fluoroethoxybenzovesmi-
col ([18F]FEOBV) positron emission tomography (PET; Aghourian
et al., 2017; Petrou et al., 2014). FEOBV is a high-affinity ligand for
the vesicular acetylcholine transporter (VAChT), the protein responsi-
ble for pumping ACh from the cytosol into synaptic vesicles (Prado
et al., 2017; Prado, Roy, Kolisnyk, Gros, & Prado, 2013). VAChT is
expressed at uniquely high levels by cholinergic neurons (Arvidsson,
Riedl, Elde, & Meister, 1997). Prior human imaging studies of brain
VAChT expression used less resolute single photon emission com-
puted tomography (SPECT) methods (Kuhl et al., 1994, 1996; Lamare
et al., 2013). Prior PET studies of regional cholinergic terminal distri-
bution used acetylcholinesterase (AChase) substrates ([11C]methyl-
4-piperidinyl propionate [PMP]; N-[11C]-methyl-4-piperidyl acetate
[MP4A]) to identify cholinergic synapses (Iyo et al., 1997; Kuhl et al.,
1999). These methods are less specific. AChase, for example, is pro-
duced by midbrain dopaminergic neurons and high regional AChase
activity was detected in regions, the lateral cerebellar cortices, not
suspected to have substantial cholinergic terminal innervation
(Greenfield, 1991; Kuhl et al., 1999). AChase enzyme activity may be
regulated by synaptic activity and disease states, a potential obstacle
to quantifying regional cholinergic terminal density (DeKosky et al.,
1992). The very high AChase expression characteristic of the striatum
limits quantification of striatal AChase as PMP and MP4A metabolite
accumulation may be flow, rather than AChase activity, limited. PMP
and MP4A are also, though to a considerably lesser extent, butyryl-
cholinesterase substrates and butyrylcholinesterase activity changes
might influence the results of PET studies with these tracers (Snyder
et al., 2001).
We describe the regional distribution of [18F]FEOBV binding in
human volunteers with no evidence of neurologic or psychiatric dis-
ease. Our results largely confirm inferences from postmortem human
studies and nonhuman mammal studies but indicate distinctive fea-
tures of human cholinergic pathways and indicate effects of aging.
2 | METHODS
2.1 | Subjects
We studied 29 subjects without histories of the neurologic or psychi-
atric disease. We studied 18 men and 11 women. The mean age was
47 years (SD = 21 years); age range 20–81 years. No subject was
using a medication that might affect cholinergic neurotransmission
and none were using tobacco or nicotine products. Informed consent
was obtained from all subjects prior to study entry and this study was
approved by the University of Michigan Medical School IRB. Limited
results were reported previously from subsets of these subjects
(Albin, Minderovic, & Koeppe, 2017; Petrou et al., 2014).
2.2 | [18F]FEOBV PET
[18F]FEOBV was prepared as described previously (Petrou et al.,
2014; Shao et al., 2011). [18F]FEOBV (288–318 MBq) was
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administered via intravenous bolus. Twenty-eight subjects were
scanned on an ECAT Exact HR+ PET tomograph (Siemens Molecular
Imaging, Knoxville, TN). One subject was scanned on a Biograph True-
Point scanner (Model 1094; Siemens Molecular Imaging). Brain imag-
ing was conducted in three imaging periods. The first period began at
injection and continued for 90 min. The subjects were then given a
30-min break, followed by a second imaging period from 120 to
150 min, an additional break, and then a third imaging period from
180 to 210 min. Dynamic PET scans were reconstructed using Fourier
rebinning (FORE) and the iterative 2D-OSEM algorithm, with four iter-
ations, 16 subsets, and no postreconstruction smoothing. The entire
dynamic sequence was co-registered to the final form of the first
90-min scanning period. The first seven studies were acquired with a
slightly different protocol, where the first scanning period last for
120 min, and the second and third periods lasted from 150 to
180 and 210 to 240 min, respectively.
2.3 | MRI
MRI imaging was performed on a 3 Tesla Philips Ingenia System
(Philips) using a 15-channel head coil. A standard T1 weighted series
of a 3D inversion recovery prepared turbo-field echo was performed
in the sagittal plane using TR/TE/TI = 9.8/4.6/1041 ms; turbo fac-
tor = 200; single average; FOV = 240 × 200 × 160 mm; acquired
matrix = 240 × 200. One hundred and sixty slices were reconstructed
to 1-mm isotropic resolution.
2.4 | Analysis of [18F]FEOBV binding
The primary analysis was performed using the average of the co-
registered 180–210 min scan period (termed “late static”). For the
seven scans that had a slightly different acquisition sequence, we used
the average of both the 150–180 and 210–240 time windows, thus
matching the median of the scan data used of 195 min. FreeSurfer
(freesurfer-i386-apple-darwin11.4.2-stable6-20170119; https://surfer.
nmr.mgh.harvard.edu/fswiki/FreeSurferMethodsCitation; RRID: SCR_
001847) was used on each individual's T1-weighted MR to define gray
matter and white matter voxels. The entire co-registered PET sequence
was registered to the MR. The segmented white matter mask from
FreeSurfer (1 for WM; 0 elsewhere) was smoothed to PET resolution,
and then a threshold of 0.90 applied to the mask, yielding a volume of
interest where the partial volume contribution from nonwhite matter
regions to the mask was <10% for every voxel. This white matter
volume-of-interest was then applied to the PET data and used as a nor-
malizing (intensity scaling) factor for the late static scan. Accordingly,
[18F]FEOBV binding in each volume of interest was expressed as stan-
dardized uptake value ratios (SUVRs). We showed previously that this
approach is equivalent to kinetic modeling approaches for quantifying
regional brain [18F]FEOBV binding (Albin et al., 2017).
We used NeuroStat (https://neurostat.neuro.utah.edu/) and Statis-
tical Parametric Mapping (SPM12; http://www.fil.ion.ucl.ac.uk/spm/;
RRID: SCR_007037) to nonlinearly warp all PET scans into the Talairach
and International Consortium for Brain Mapping atlas spaces, respec-
tively. This was done to allow the creation of mean images of all sub-
jects, plus mean images for young and elderly cohorts, and to allow
better visualization of effects of aging. We also used our standard VOI
set developed for Talairach space, which is based entirely on the PET
scans (no MR), as described previously (Bohnen et al., 2006). Brainstem
parcellation was performed as described previously (Albin et al., 2008).
To complement this regional analysis, cortical and subcortical segmen-
tation was performed with FreeSurfer. The programs were run in the
fully automated mode. Volumes for all FreeSurfer-defined brain struc-
tures were obtained as part of the standard FreeSurfer output. The
VOIs were then applied in native MR-space to the co-registered PET
scans. Results were essentially identical to those of the Neurostat-SPM
based analysis and are not shown.
To analyze thalamic [18F]FEOBV binding, we used the FreeSurfer-
defined thalami, assumed an ellipsoid volume, and estimated the long
axis of the ellipsoid volume. We then divided each hemisphere of the
thalamus into octants, based on voxels medial versus lateral, anterior
versus posterior, and superior versus inferior to the axis.
2.5 | Aging effects
To assess potential aging effects, we took advantage of the fact that
our study population was divided into two groups; a younger group
(N = 13; Mean 25 years; range 20–38) and an older group (N = 16;
Mean 66 years; range 52–81). Inspection of averaged images for
these groups suggested regionally specific age-related declines in
[18F]FEOBV binding accompanying aging. Selected regions exhibiting
possible age-related declines were compared with regions that
appeared unchanged with aging. Examined regions included the stria-
tal complex, thalamus, primary sensorimotor cortex (BAs 1–35), ante-
rior cingulate cortex (BAs 24,32), hippocampal formation, amygdala,
posterior cingulate cortex (BAs 23,31), cerebellar vermis, occipital cor-
tex (BAs 17–19), lateral frontal cortex (BAs 44–47), and medial frontal
cortex (BAs 8–10).
2.6 | Statistical analysis
[18F]FEOBV binding was compared within some regions using stan-
dard parametric methods. Analyses are described in each relevant
Results section.
3 | RESULTS
3.1 | Overall
Brain [18F]FEOBV binding was distributed inhomogeneously (Figure 1;
Table 1). Binding was highest in the striatal complex, followed by por-
tions of the thalamus, amygdala and hippocampal formation, some
neocortical regions, rostral brainstem, and some regions of the cere-
bellar cortex. The overall distribution and regional density of [18F]
FEOBV binding is largely consistent with the distribution of choliner-
gic terminals described in prior human postmortem and nonhuman
mammal studies (Albin et al., 1994; Barmack, Baughman, & Ecken-
stein, 1992; Barmack, Baughman, Eckenstein, & Shojaku, 1992; de
Lacalle et al., 1993, 1994; Emre et al., 1993; Fitzpatrick et al., 1989;
Fukushima et al., 2001; Gilmor et al., 1996, 1999; Heckers et al.,
1992; Ichikawa et al., 1997; Jaarsma et al., 1997; Levey et al., 1987;
2886 ALBIN ET AL.
Mahady et al., 2017; Manaye et al., 1999; Mesulam, 2004; Mesulam
et al., 1989; Mesulam & Geula, 1988; Mesulam, Hersh, et al., 1992;
Mesulam, Mash, et al., 1992; Roghani et al., 1998; Schafer et al.,
1995; Schäfer et al., 1998; Woolf, 1991; Woolf et al., 1984; Woolf &
Butcher, 1985, 1986, 1989; Zhang et al., 2016). Our results are con-
sistent as well with prior VAChT ligand human SPECT imaging studies
(Kuhl et al., 1994, 1996; Lamare et al., 2013).
Our results likely identify the distribution of and quantify the
regional density of major cholinergic terminal systems in the human
brain; cholinergic projections originating in the BF, striatal cholinergic
interneurons, ascending and descending projections from the PPN/LDT
complex, and cholinergic MVC projection neurons. It was not possible
to clearly identify cholinergic nuclei or terminals associated with the
medial habenular–interpeduncular nucleus projection or the parabigem-
inal nucleus to collicular projection, though the parabigeminal nucleus
may be included in a region of relatively high [18F]FEOBV binding at
the mesopontine junction (see below). It was not possible to identify
brainstem motor or autonomic cholinergic nuclei. More detailed
description of the identifiable projections–regions follows.
3.2 | Striatal complex
Consistent with the known very high expression of cholinergic
markers in the striatal complex, striatal complex [18F]FEOBV binding
was the highest of all brain regions, well above levels expressed in any
other region. Striatal complex [18F]FEOBV binding was mildly
FIGURE 1 [18F]FEOBV binding in human brain. (a) Dorsal to ventral survey of averaged transaxial images for all 29 subjects. Images scaled
to peak SUVR of 3.0. Regions with notable [18F]FEOBV binding include the striatal complex, thalamus, amygdala, hippocampal formation,
neocortical mantle, mesonpontine junction, and portions of the cerebellum (see text for details). (b) Pseudocolor images of dorsal transaxial levels
(identical to top row in [a] above) to illustrate differing [18F]FEOBV binding in different cortical regions. Scaled to peak SUVR of 2.5. These images
demonstrate relatively higher [18F]FEOBV binding in primary sensorimotor and anterior cingulate cortices
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heterogeneous. [18F]FEOBV binding was highest in the putamen and
lower in the caudate nucleus (Table 1; paired t test, p < .0001). The
striatal complex was further subdivided in dorsal caudate, ventral stri-
atum (nucleus accumbens and ventral caudate), anterior putamen, and
posterior putamen (Table 1). [18F]FEOBV binding was modestly differ-
ent in all these subregions (one-way ANOVA for correlated samples,
p < .0001; all subregions different from each other, Tukey's HSD,
p < .01). The rank order of striatal complex [18F]FEOBV binding was
Anterior Putamen > Posterior Putamen > Dorsal Caudate > Ventral
Striatum.
3.3 | Cortex
[18F]FEOBV binding was distributed widely and somewhat inhomo-
geneously throughout the cortex. Most neocortical regions (BA1–23,
26, 29–32, 36–47; Figures 1 and 2) exhibited modest [18F]FEOBV
binding (mean SUVRs = 1.5–2.0 range; Table 1) with some regions
(BA24, 25, 27, 28, 34, and 35) exhibiting higher levels of [18F]FEOBV
binding (mean SUVRs = 2.0–2.5 range; Table 1). Consistent with the
results of the Brodmann areas based analysis, primary sensorimotor
and anterior cingulate cortices were readily distinguished from
surrounding cortices (Figures 1 and 2). Similarly, there was a modest
anterior to posterior gradient with frontal cortices exhibiting modestly
higher levels of [18F]FEOBV binding than occipital cortices (Figures 1
and 2). Insular cortex was slightly higher (mean SUVR = 2.57; Table 1)
As expected, the hippocampal formation (mean SUVR = 2.76) and
amygdala (mean SUVR = 3.14) exhibited the highest [18F]FEOBV
binding of any cortical region (Table 1, Figure 3).
3.4 | Thalamus
The thalamus exhibited relatively high but likely inhomogeneous [18F]
FEOBV binding (Table 1, Figures 1 and 4). Grossly, thalamic [18F]
FEOBV binding distribution did not exhibit the expected ovoid shape
(Figures 1 and 4). In particular, the anterolateral border of thalamic
[18F]FEOBV binding had a concave shape, suggesting less [18F]FEOBV
binding in the anterolateral thalamus. In addition, the lateral geniculate
nuclei exhibited high [18F]FEOBV binding and could be easily distin-
guished from the rest of the thalamus (Table 1, Figure 4). This sug-
gests that portions of the thalamus more rostral and dorsal to the
lateral geniculate nucleus, for example, portions of the pulvinar com-
plex, had less [18F]FEOBV binding. In the absence of an established
TABLE 1 Bilaterally averaged [18F]FEOBV binding within selected volumes of interest
Region Mean SUVR SD Region Mean SUVR SD
BA1 1.80 0.19 BA43 1.84 0.18
BA2 1.77 0.17 BA44 1.78 0.14
BA3 1.84 0.20 BA45 1.70 0.15
BA4 1.92 0.23 BA46 1.68 0.15
BA5 1.74 0.19 BA47 1.81 0.15
BA6 1.87 0.19 Amygdala 3.14 0.39
BA7 1.60 0.13 Hippocampal formation 2.76 0.31
BA8 1.66 0.14 Insula 2.57 0.29
BA9 1.71 0.13 Caudate 7.67 1.31
BA10 1.69 0.14 Dorsal caudate 8.00 1.41
BA11 1.67 0.14 Ventral striatum 7.00 1.29
BA12 1.82 0.18 Putamen 8.89 1.43
BA17 1.53 0.15 Anterior putamen 9.01 1.47
BA18 1.48 0.12 Posterior putamen 8.53 1.40
BA19 1.52 0.12 Thalamus 3.45 0.57
BA20 1.65 0.16 Lateral geniculate nucleus 3.47 0.60
BA21 1.73 0.15 Cerebellar hemisphere cortex 1.80 0.16
BA22 1.89 0.17 Cerebellar vermis cortex 3.08 0.38
BA23 1.68 0.14 Flocculus 2.22 0.33
BA24 2.12 0.23 Midbrain 2.35 0.28
BA25 2.89 0.63 Substantia Nigra 2.01 0.27
BA26 1.87 0.27 Raphe nucleus 2.61 0.41
BA27 2.37 0.57 Dorsal midbrain 2.85 0.30
BA28 2.50 0.39 Pons 2.09 0.25
BA29 1.45 0.14 Rostral pons 2.35 0.28
BA30 1.65 0.23 Caudal Pons and Medulla 2.38 0.25
BA31 1.75 0.14 Medulla 2.05 0.28
BA32 2.01 0.20
BA34 2.71 0.40
BA35 2.20 0.35
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parcellation of the thalamus, we divided the thalamus into eight subre-
gions by assuming that the thalamus has ovoid shape with a major
rostral-caudal axis, excluding the lateral geniculate nuclei (see
section 2). In general, consistent with the impression that anterolateral
regions exhibited less [18F]FEOBV binding, the lateral subregions
defined by this analysis had less [18F]FEOBV binding than medial sub-
regions and anterior subregions had less [18F]FEOBV binding than
posterior regions (Table 2). This was confirmed by statistical compari-
sons of cognate octants (e.g., superior anterolateral octant vs. superior
anteromedial octant; superior anterolateral octant vs. superior pos-
terolateral octant, etc.). All medial octants had significantly higher
[18F]FEOBV binding than cognate lateral octants and all posterior
octants had significantly higher [18F]FEOBV binding than cognate
anterior octants (p < 0.05; paired t tests with Bonferroni correction
for multiple comparisons). This approach may not sample the pulvinar
complex adequately. As seen in Figure 4B, the lateral geniculate nuclei
appear relatively isolated, suggesting that the pulvinar complex, rostral
and dorsal to the lateral geniculate, exhibits relatively low [18F]FEOBV
binding.
3.5 | Cerebellum
All regions of cerebellar cortex exhibited [18F]FEOBV binding with
some regions exhibiting relatively high [18F]FEOBV binding levels
(Table 1, Figures 1 and 5). Highest cerebellar cortical [18F]FEOBV
binding was found in the vermis (mean SUVR = 3.1) with the cerebel-
lar hemisphere cortices at significantly lower levels (mean SUVR = 1.8).
The floccular region exhibited intermediate levels of [18F]FEOBV
binding (mean SUVR = 2.2).
3.6 | Brainstem
Significant [18F]FEOBV binding (mean SUVRs in the 2–2.5 range) was
present in all regions quantified (Table 1). Precise parcellation of the
brainstem is very limited due to the small size of brainstem structures
such as PPN–LDT complex and cranial nerve nuclei. [18F]FEOBV bind-
ing was particularly concentrated in dorsal brainstem from the caudal
midbrain to the mid pons (Figures 1 and 6). While difficult to quantify,
there also appeared to be modestly increased [18F]FEOBV binding in
the dorsal regions of the caudal brainstem, possibly within the peria-
queductal tegmentum (Figures 1 and 6).
3.7 | Aging effects
Potential aging effects were assessed initially by comparing younger
(22–38 years) and older (52–81 years) subjects. These comparisons
revealed regionally specific changes accompanying aging (Table 3, Fig-
ures 7 and 8). Statistical significance of age-related changes was
assessed with one-way independent t tests using the Holm–
Bonferroni method to correct for multiple comparisons at a threshold
of p < .05. Significant age-related changes were found in the striatum,
primary sensorimotor cortex, and anterior cingulate cortex with trends
FIGURE 2 Neocortical [18F]FEOBV binding. Transaxial images from near the vertex to the level of the striatum. Images scaled to emphasize
differences in cortical regions. Consistent with Brodmann area based analysis (Table 1; see text), higher [18F]FEOBV binding in primary
sensorimotor (SMC) and anterior cingulate (AC) cortices. There is a modest anterior to posterior gradient with higher frontal cortical than occipital
cortical [18F]FEOBV binding
FIGURE 3 [18F]FEOBV binding in amygdala and hippocampal
formation. (a,b) [18F]FEOBV binding. (a) Transaxial averaged image of
all 29 subjects at level of anterior temporal lobe. (b) Parasagittal
averaged image of all 29 subjects at level of amygdala (AM) and
hippocampal formation (HIP). (c,d); early phase averaged images,
representing the relative regional blood–brain ligand transport rate—
Regional anatomy. (a,b) show significant [18F]FEOBV binding and
easily distinguishable amygdala and hippocampal formation
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towards age-related declines in the thalamus, hippocampal formation,
amygdala, and posterior cingulate (Table 3). There was no evidence of
age-related decline in the cerebellar vermis and other cortical regions
(Table 3). To further explore the relationship between aging and
regional [18F]FEOBV binding, age was regressed against [18F]FEOBV
binding in selected regions (Pearson product–moment correlations;
Figure 8). Strong negative correlations were present in striatum
FIGURE 4 Thalamic [18F]FEOBV binding. Pseudocolor images of [18F]FEOBV binding (top row) and relative regional blood–brain ligand transport
rate—Regional anatomy (bottom row). (a) Transaxial and parasagittal images at levels of dorsal thalamus (THAL). Note the inverted comma shape
of high density of [18F]FEOBV binding in thalamus in the transaxial image compared with the ovoid shape of the thalamus in the transaxial flow
image. (b) Transaxial and parasagittal images at levels of the lateral geniculate nuclei (LG). Not the relative isolation of high [18F]FEOBV binding in
the lateral geniculate nuclei compared with surrounding regions, particularly the more anterior and dorsal pulvinar complex
FIGURE 6 Brainstem [18F]FEOBV binding. Pseudocolor parasagittal
images of [18F]FEOBV binding (top) and relative regional blood–brain
ligand transport rate—Regional anatomy (bottom) in the midline plane.
Relatively high [18F]FEOBV binding in the dorsal midbrain and
spanning the mesopontine junction into rostral pons (MP). Increased
[18F]FEOBV binding within the more dorsal caudal brainstem, possibly
around the aqueduct
TABLE 2 Bilaterally averaged thalamic octant SUVRs
Octant Mean SUVR SD
Superior anterior lateral 2.82 0.57
Superior anterior medial 3.15 0.55
Superior posterior lateral 3.40 0.71
Superior posterior medial 3.53 0.70
Inferior anterior lateral 2.79 0.53
Inferior anterior medial 3.61 0.48
Inferior posterior lateral 3.28 0.74
Inferior posterior medial 4.09 0.61
FIGURE 5 Cerebellar [18F]FEOBV binding. Pseudocolor images of
[18F]FEOBV binding (top row) and relative regional blood–brain ligand
transport rate—Regional anatomy (bottom row). (a) Transaxial images
at the level of flocculi (FL). Note relatively high [18F]FEOBV binding in
the floccular region, anterior vermis (VER), and posterior vermis (VER)
with less [18F]FEOBV binding in the cerebellar hemispheres.
(b) Parasagittal images at the level of the flocculus. (c) Coronal images
at the level of the vermis. Again, note relatively high [18F]FEOBV
binding in the vermis compared with the cerebellar hemispheres
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TABLE 3 Age-related regional changes in [18F]FEOBV binding. Values are SUVRs
Region Young subject mean (SD) Older subject mean (SD) p
Striatal complex 9.16 (1.12) 7.39 (0.96) <.0001*
Primary sensorimotor cortex 1.92 (0.15) 1.73 (0.96) .002*
Anterior cingulate cortex 2.18 (0.16) 1.97 (0.20) .0023*
Thalamus 3.68 (0.43) 3.26 (0.61) .024
Hippocampal formation 2.89 (0.32) 2.66 (0.28) .026
Posterior cingulate cortex 1.76 (0.11) 1.68 (0.14) .062
Amygdala 3.26 (0.36) 3.05 (0.40) .071
Cerebellar vermis 3.16 (0.49) 3.02 (0.26) .165
Occipital cortex 1.52 (0.08) 1.50 (0.15) .325
Medial frontal cortex 1.69 (0.08) 1.66 (0.16) .280
Lateral frontal cortex 1.76 (0.08) 1.73 (0.17) .300
*Significant after Holm–Bonferroni correction.
FIGURE 7 Effects of aging on [18F]FEOBV binding. (a) Averaged transaxial pseudocolor images scaled at a peak of 10.0. a1 and a3—Young
normal subjects. a2 and a4—Older normal subjects. Note declines in [18F]FEOBV binding in primary sensorimotor and anterior cingulate cortices
in older normal subjects. (B) Averaged transaxial pseudocolor images scaled at a peak of 3.0 and at the levels of the striatal complex. b1—Young
normal subjects. b2—Older normal subjects. Note decline in striatal complex [18F]FEOBV binding in older subjects
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(r = .68; p < .00003; decline of ~4% per decade), primary sensorimotor
cortex (r = .52; p < .003; decline of ~2.5% per decade), and anterior cingu-
late cortex (r = .55; p < .001; decline of ~2.5% per decade), and thalamus
(r = 0.42; p < .0125; decline of ~2.5% per decade). All correlations signifi-
cant after Bonferroni correction at a threshold of 0.05. An interesting
example of regionally specific decrease in [18F]FEOBV binding was found
in the primary sensorimotor cortex. In younger subjects, this region was
easily distinguished from surrounding cortices by higher [18F]FEOBV
binding (Figure 7). In older subjects, primary sensorimotor cortex [18F]
FEOBV binding appeared more similar to surrounding cortices (Figure 7).
4 | DISCUSSION
VAChT is thought to be uniquely expressed by cholinergic neurons. The
VAChT gene is part of a distinctive cholinergic “operon,” encoded within
the first exon of the Choline Acetyltransferase gene (Eiden, 1998). FEOBV
is a high affinity and specific ligand for VAChT (Mulholland et al., 1998). In
general, our findings correlate well with prior studies of brain cholinergic
systems in humans and other mammals based on ChAT and high-affinity
choline transporter immunohistochemistry (Kus et al., 2003; and see
below). Our results also correlate well with nonhuman animal and limited
human studies of the distribution of brain VAChT immunoreactivity
(Arvidsson et al., 1997; Gilmor et al., 1996, 1999; Ichikawa et al., 1997;
Roghani et al., 1998; Schafer et al., 1995; Schäfer et al., 1998). Our results
also correspond very well with prior limited human PET imaging with [18F]
FEOBV (Aghourian et al., 2017; Albin et al., 2017; Petrou et al., 2014).
4.1 | Striatal complex
The striatal complex exhibited the highest regional [18F]FEOBV bind-
ing, indicating a very high density of cholinergic terminals within the
striatal complex. This result is consistent with a large body of data
from studies in many species indicating uniquely high expression of
cholinergic system markers and terminals in the striatal complex.
There are at least two, and possibly three, sources of striatal choliner-
gic terminals. While striatal cholinergic interneurons comprise only a
small fraction (~2–3%) of the total striatal neuron population
(Bernácer, Prensa, & Giménez-Amaya, 2007; Gonzales & Smith, 2015;
Lecumberri, Lopez-Janeiro, Corral-Domenge, & Bernacer, 2018) they
give rise to dense axonal-terminal arborizations and play an important
role in the integration of cortico- and thalamo-striate inputs with
dopaminergic functions. The striatal complex also receives innervation
from mesopontine (PPN–LDT) cholinergic neurons (Dautan et al.,
2014; Dautan, Hacioglu Bay, Bolam, Gerdjikov, & Mena-Segovia,
2016; Woolf, 1991), presumably collaterals of neurons innervating the
thalamus and other targets of the PPN-LDT complex. Mesulam,
Hersh, et al. (1992) suggested that the human striatal complex
receives some cholinergic afferents from the basal forebrain complex,
a projection that is absent in rodents (Dautan et al., 2016). The rela-
tive proportion of striatal cholinergic interneuron terminals and extrin-
sic afferent terminals is unknown. It is generally assumed that striatal
cholinergic interneuron terminals are much more abundant than
extrinsic cholinergic afferent terminals. Janickova et al. (2017) geneti-
cally ablated VAChT in murine PPN-LDT neurons. As measured by
western immunoblots, VAChT protein expression diminished markedly
in the brainstem and thalamus and was unchanged in hippocampal
formation, neocortex, and striatum. Genetic or toxic ablation of stria-
tal cholinergic interneurons results in marked reductions in striatal
cholinergic terminal markers (Aoki, Liu, Zucca, Zucca, & Wickens,
2015; Laplante, Lappi, & Sullivan, 2011; Martos, Braz, Beccaria,
Murer, & Belforte, 2017; Pappas et al., 2015). These results are con-
sistent with the traditional view that striatal extrinsic cholinergic affer-
ents contribute only modestly to the total density of striatal
cholinergic terminals. This is not to say that extrinsic cholinergic stria-
tal afferents are functionally unimportant.
Our data suggest modest inhomogeneity of striatal cholinergic
terminal density. [18F]FEOBV binding was higher in the putamen than
the caudate. Further subdividing these regions, we found highest [18F]
FEOBV binding within in the anterior putamen and lowest in the ven-
tral striatum. In a stereological analysis of human postmortem mate-
rial, Bernácer et al. (2007) described the inhomogeneous distribution
of striatal cholinergic interneuron perikarya with higher density in the
caudate nucleus than putamen. This is somewhat discordant with our
results. While their definition of subregions is somewhat different
from ours, their definition of caudate and putamen approximate our
definition of dorsal caudate nucleus and putamen. The differences
between our results and those of Bernácer et al. (2007) cautions
against simple equation of perikaryal density and terminal density.
Mesulam, Mash, et al. (1992) suggested that human cholinergic basal
forebrain projections to the striatal complex more heavily innervate
the putamen.
4.2 | Cortex
The cortical mantle receives its cholinergic inputs from cholinergic
neurons of the basal forebrain complex (Ch1–Ch4 in the
FIGURE 8 Correlations between age and regional [18F]FEOBV
binding. Pearson product–moment correlations between subject age
and regional [18F]FEOBV binding in striatum, primary sensorimotor
cortex, anterior cingulate cortex, and thalamus. All correlations
significant after Bonferroni correction at a threshold of 0.05
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nomenclature of Mesulam, Mufson, Wainer, & Levey, 1983). These
cholinergic projections are known to participate in several important
cognitive processes including attention, executive functions, and
forms of memory (Ballinger et al., 2016; Hasselmo & Sarter, 2011;
Prado et al., 2017). Our results are broadly consistent with data from
older analyses of cholinergic terminal markers in human postmortem
specimens (de Lacalle et al., 1994; Emre et al., 1993; Mesulam, 2004,
2013; Mesulam & Geula, 1988; Mesulam, Hersh, et al., 1992). Consis-
tent with these prior descriptions, highest [18F]FEOBV binding was
found in amygdala and hippocampal formation, followed by paralimbic
cortices, including the insular cortex, perirhinal cortex (BA35), entorhi-
nal cortex (BA34, BA28), parahippocampal gyrus (BA27), and portions
of the cingulate cortex (BA25, BA24). Regional binding density is
probably not the only important difference in cholinergic innervation
between cortical regions. Mesulam, Hersh, et al. (1992) also described
varying laminar distributions of cholinergic terminals between neocor-
tical regions. Detecting such differences is beyond the resolution of
PET imaging. Similarly, prior studies indicate that the basolateral
amygdala exhibits the highest density of cholinergic terminals with
other amygdala nuclei exhibiting significantly less cholinergic innerva-
tion (Emre et al., 1993).
4.3 | Thalamus
Analysis of the thalamus was limited by lack of an accepted parcella-
tion method for thalamic subnuclei. Nonetheless, our data suggest sig-
nificant inhomogeneity for [18F]FEOBV binding within the thalamus.
The lateral geniculate nuclei exhibited significant [18F]FEOBV binding.
Visual inspection suggests less [18F]FEOBV binding in anterior, lateral
and some posterior (pulvinar) thalamic subregions. These conclusions
are consistent with analysis based on the arbitrary division of the thal-
amus into eight equivalent octants. Lateral regions exhibited less [18F]
FEOBV binding than medial regions and anterior regions less [18F]
FEOBV binding than posterior regions. This crude parcellation
approach may not adequately assess [18F]FEOBV binding in the pulvi-
nar complex, which likely also exhibits lower [18F]FEOBV binding.
Our results are consistent with the work of Heckers et al. (1992)
assessing cholinergic terminal density with ChAT immunohistochemis-
try in human postmortem specimens. Heckers et al. (1992) documen-
ted ChAT immunoreactive fibers throughout the human thalamus
with the greatest density of ChAT-immunoreactive fibers in the lateral
geniculate nuclei, some intralaminar nuclei, the reunions nucleus, the
anterodorsal nucleus, the reticular nucleus, and some portions of the
mediodorsal nucleus. Lowest density of ChAT-immunoreactive fibers
was seen in the pulvinar and medial geniculate nuclei. As Heckers
et al. (1992) point out the human subregional distribution of thalamic
cholinergic terminals is likely distinct from that found in the limited
number of other species studied (Fitzpatrick et al., 1989; Levey
et al., 1987).
The major cholinergic innervation of thalamus originates in the
PPN–LDT complex with some contribution from the basal forebrain.
PPN–LDT cholinergic efferent projections generally ramify widely and
innervate several target regions (Mena-Segovia & Bolam, 2017),
though Holmstrand and Sesack (2011) suggest some specialization of
cholinergic PPN–LDT afferents targeting the anterior thalamus. In
humans, basal forebrain cholinergic afferents probably innervate more
anterior and medial thalamic nuclei, including the central medial and
central lateral nuclei, and portions of the mediodorsal nucleus
(Heckers et al., 1992).
Cholinergic afferents to the thalamus are implicated in several
important phenomena, notably the regulation of consciousness and
sleep, though the abundance of cholinergic terminals and receptors
within the thalamus suggests cholinergic neurotransmission may mod-
ulate multiple aspects of thalamic function. Recent work, for example,
from our group suggests that thalamic cholinergic neurotransmission
contributes to “bottom-up” detection of salient sensory cues (Kim,
Müller, Bohnen, Sarter, & Lustig, 2017).
4.4 | Cerebellum
Prior work in several species suggests significant cholinergic innerva-
tion of some cerebellar regions (Barmack, Baughman, & Eckenstein,
1992; Barmack, Baughman, Eckenstein, & Shojaku, 1992; de Lacalle
et al., 1993; Fukushima et al., 2001; Jaarsma et al., 1997; Manaye
et al., 1999; Zhang et al., 2016). There is no evidence of cholinergic
neurons within the cerebellum in most species studied. Cholinergic
terminals were detected throughout the cerebellar cortex, though
most studies describe these as relatively sparse in most cerebellar cor-
tical regions. [18F]FEOBV PET is likely to convey a more faithful repre-
sentation of cerebellar cortical innervation than AChase PET methods,
which show uniform and high cerebellar cortical tracer retention. Bar-
mack and colleagues (Barmack, Baughman, & Eckenstein, 1992; Bar-
mack, Baughman, Eckenstein, & Shojaku, 1992) described relatively
high levels of cholinergic innervation of some cerebellar cortical
regions in rat, rabbit, car, and nonhuman primate brain. These included
the uvula-nodulus (lobules 9 and 10), the floccular region, and the
anterior vermis (lobules 1 and 2) (Barmack, Baughman, & Eckenstein,
1992; Barmack, Baughman, Eckenstein, & Shojaku, 1992). The pre-
dominant source of these terminals appears to be cholinergic neurons
of the vestibular complex. Jaarsma et al. (1997) also described cholin-
ergic afferents to the cerebellar cortex from numerous brainstem
populations, though MVC cholinergic neurons were felt to be the pre-
dominant source of cerebellar cortical afferents. de Lacalle
et al. (1993) described a ChAT-immunoreactive subpopulation of cere-
bellar cortical Golgi interneurons, particularly in the vermis, uvula-
nodulus, and flocculus, in human postmortem specimens.
We find uniformly high [18F]FEOBV binding throughout the ver-
mis, different from the patterns described in other mammals. The orig-
inating neurons of this extensive cerebellar vermis cholinergic
innervation are unknown, though it is possible that it is an extension
of the vestibulocerebellar cholinergic innervation documented in
other mammals. Alternatively, the pattern of cerebellar [18F]FEOBV
binding may reflect the distribution of cholinergic Golgi interneurons
described by de Lacalle et al. (1993). The vestibular system plays a
critical role in the maintenance of normal upright posture and gait, as
does the cerebellar vermis. A plausible speculation is that extended
vestibular cholinergic innervation of the cerebellar vermis is a corre-
late of bipedal locomotion in humans. Seidel et al. (2015) document
α-synuclein aggregate pathology in the MVC nuclei of postmortem
specimens from individuals with Parkinson disease and Lewy body
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dementia. It is possible that vestibular dysfunction contributes to the
dopamine replacement therapy refractory gait and balance deficits of
advanced Parkinson disease.
Another previously documented site of cholinergic innervation of
the cerebellum is the deep cerebellar nuclei. Prior tract-tracing and
functional studies in rodents indicate projections from the PPN-LDT
complex to the deep cerebellar nuclei with MRI tractography studies
supporting the existence of this projection in humans (Aravamuthan,
Muthusamy, Stein, Aziz, & Johansen-Berg, 2007; Vitale et al., 2016).
These terminals are presumably too sparse to be detected by [18F]
FEOBV PET.
4.5 | Brainstem
Cholinergic neurons within the brainstem include oculomotor (CrN III,
IV, and VI nuclei), motor (motor nucleus of CrN V, and CrN VII, CrN X,
XI, and CrN XII nuclei), and autonomic nuclei (Vagal Nucleus), and
some MVC neurons. Most of these nuclei are beyond the resolution
of PET imaging. The largest collection of brainstem cholinergic neu-
rons lies within the PPN-LDT complex (Mesulam et al., 1983, Chap-
ter 5 and 6). In immunohistochemical studies of postmortem human
specimens, Mesulam et al. (1989) described the PPN–LDT complex as
stretching from the dorsal mid-mesencephalon to dorsal mid-pons.
The distribution of cholinergic perikarya did not observe specific
nuclear borders nor was it delimited by fiber tracts. Cholinergic peri-
karya were distributed at varying densities throughout this volume of
the brainstem. Similar results were obtained by Manaye et al. (1999).
In rodent PPN–LDT, there is a rostrocaudal gradient of cholinergic
perikarya density with the highest density of these neurons in the
caudal PPN–LDT complex (Mena-Segovia & Bolam, 2017). The distri-
bution of cholinergic perikarya described in humans by Mesulam
et al. (1989) coincides well with the distribution of relatively high [18F]
FEOBV binding we find spanning the dorsal mesopontine junction.
This area of relatively high brainstem [18F]FEOBV binding may also
include the cholinergic parabigeminal nucleus (Mesulam et al., 1983,
Chapter 8), adjacent and lateral to the PPN-LDT complex in the
upper pons.
We found significant [18F]FEOBV binding throughout the brain-
stem, most likely the binding to the terminals of PPN–LDT neurons
that innervate multiple targets throughout the brainstem (Woolf &
Butcher, 1989). While our analysis is limited by the resolution of PET,
prior studies in other species do not describe marked inhomogeneity
of brainstem cholinergic terminals. It was possible to tentatively iden-
tify what might be a column of relatively increased [18F]FEOBV bind-
ing in the dorsal caudal brainstem surrounding the aqueduct
(Figures 1 and Figure 5).
4.6 | Aging effects
Our results indicate significant and regionally specific declines in [18F]
FEOBV binding. Striatal complex changes are consistent with age-
related declines in striatal cholinergic interneuron terminal density.
There was a suggestion of reduced thalamic [18F]FEOBV binding, con-
sistent with age-related decrease in PPN–LDT complex cholinergic
terminals. Ransmayr et al. (2000) described age-related loss of PPN
neurons in humans. Zhang, Sampogna, Morales, & Chase (2005) stud-
ied PPN–LDT neurons in aged cats. There was no evidence of PPN–
LDT cholinergic perikarya loss but there was evidence of neuronal
atrophy and dendritic simplification. Prior work suggests age-related
changes in BF neurons. MRI morphometry studies indicate age-related
loss of BF nuclear volumes (Grothe, Heinsen, & Teipel, 2012; Hanyu
et al., 2002). These results are consistent with our data suggesting
age-related loss of BF corticopetal terminals. Our data suggest that
this is not a uniform process as we found cortical regions (primary
sensorimotor cortex, anterior cingulate cortices) with significant
declines in [18F]FEOBV binding and others with little or no age-related
change. As subpopulations of BF neurons are thought to project to
relatively restricted cortical regions (Gielow & Zaborszky, 2017), our
results suggest inhomogeneous age-related changes within the BF
complex. Prior SPECT studies of human VAChT distribution also sug-
gested age-related decline in BF corticopetal terminals but lacked the
precision to resolve changes in individual neocortical regions (Kuhl
et al., 1996).
4.7 | General conclusion
[18F]FEOBV PET delineates regional cholinergic terminals well in
human brains. The general pattern of [18F]FEOBV binding is highly
consistent with the known organization of major cholinergic systems
in mammalian brain. Our results indicate distinctive organization of
cholinergic terminals in the human neocortex, cerebellar cortex, and
the human thalamus. Our results indicate the presence of age-related
and region-specific changes in cholinergic terminal density. [18F]
FEOBV PET is likely to be a useful method for studying disease states,
including several neurodegenerative disorders and psychiatric
disorders.
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